# 바이오스페이스 일일 뉴스 리포트 - 2025년 09월 26일


## 주요 헤드라인

1. **Immuneering Asset Nearly Doubles Overall Survival in Pancreatic Cancer After 9 Months (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/immuneering-asset-nearly-doubles-overall-survival-in-pancreatic-cancer-after-9-months>

2. **Immuneering Asset Nearly Doubles Overall Survival in Pancreatic Cancer After 9 Months (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/immuneering-asset-nearly-doubles-overall-survival-in-pancreatic-cancer-after-9-months>

3. **Lilly Cuts Mid-Stage Obesity Study of Muscle-Sparing Antibody (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/lilly-cuts-mid-stage-obesity-study-of-muscle-sparing-antibody>

4. **Harmony Fails Pivotal Fragile X Syndrome Trial, Blames High Placebo Response (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/harmony-fails-pivotal-fragile-x-syndrome-trial-blames-high-placebo-response>

5. **As Kennedy Takes Aim at Childhood Vaccines, a History of Merck’s ProQuad (#뉴스)**
   - Article content not available
   <https://www.biospace.com/policy/as-kennedy-takes-aim-at-childhood-vaccines-a-history-of-mercks-proquad>

6. **As Kennedy Takes Aim at Childhood Vaccines, a History of Merck’s ProQuad (#뉴스)**
   - Article content not available
   <https://www.biospace.com/policy/as-kennedy-takes-aim-at-childhood-vaccines-a-history-of-mercks-proquad>

7. **To Compete in Obesity, Late Entrants Invest Early in Manufacturing (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/to-compete-in-obesity-late-entrants-invest-early-in-manufacturing>


---
*2025년 09월 26일 바이오스페이스 뉴스 피드에서 생성된 리포트*